This project aims to utilize 177Lu and 225Ac conjugated with FAP for targeted imaging and therapy in solid tumors, focusing on cancer-associated fibroblasts (CAFs). Additionally, it seeks to investigate the synergistic effects of PD-L1 immunotherapy or chemotherapy with FAP-targeted radionuclide therapy, aiming to enhance treatment efficacy beyond single modalities. Preclinical tests will explore various radiopharmaceuticals for PTRT targets and identify immune targets that may improve efficacy through better crosstalk with RLT. Moreover, the project aims to address cases of alpha/beta irresponsive and PD-1/PD-L1 inhibitor-resistant patients to develop more effective treatments.
